Pharmaceutical company Biovitrum

A Swedish specialist pharmaceutical company with a global presence

The lack of satisfactory treatments for uncommon diseases increases the need for specialist drugs. Biovitrum’s goal is to become an international market leader in protein-based drugs for patients receiving specialist care. Through the acquisition of three unique protein-based drugs in 2008 Biovitrum has developed into an international specialist biopharmaceutical company.

Our products

Biovitrum is dedicated in helping people to a better life by developing new and innovative products to counter unmet medical needs

Biovitrum to present on June 9
On June 9, Dr Martin Nicklasson, the CEO of the Swedish pharmaceutical company Biovitrum is scheduled to present at Goldman Sachs 30th Annual Global Healthcare Conference in New York, USA. The

Presentation of Biovitrum's Interim Report Jan – Mar, 2009, April 28
Biovitrum's CEO Martin Nicklasson and CFO Göran Arvidson will Tuesday April 28 at 2 p.m. local time (CET) give a presentation of Biovitrum’s Interim Report for the first quarter 2009. Intern

Image of baby stroller Our world

The pharmaceutical industry faces major challenges. Today’s genetic tools and better diagnostics create a brand new framework. In the future we will see increased demand for drugs designed to meet the needs of the individual patient.